文献速递消化系统肿瘤

纳武利尤单抗联合伊匹木单抗新辅助治疗局部MSI-H胃/胃食管交界腺癌的2期NEONIPIGA非随机临床试验长期随访

Nivolumab-Ipilimumab for Localized Microsatellite Instability-High Gastric/Gastroesophageal Junction Adenocarcinoma: The Phase 2 NEONIPIGA Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-10-15

NEONIPIGA是一项法国多中心单臂2期非随机试验,评估纳武利尤单抗联合伊匹木单抗新辅助治疗局部dMMR/MSI-H胃或胃食管交界腺癌的长期疗效。32例患者中位随访48.3个月,4年OS为84.1%,可手术者4年EFS为83.5%,pCR率59%。免疫治疗方案与持续长期生存相关,但未观察到优于单纯手术的明确证据。

要点

  • 新辅助纳武利尤单抗联合伊匹木单抗在局部MSI-H胃/GEJ腺癌中4年OS达84.1%。
  • 可手术患者4年EFS为83.5%,pCR率59%。
  • 未手术者均获临床完全缓解,提示器官保留策略值得探索。

核心结论

  • 该免疫治疗方案与持续长期生存相关,但无明确证据表明优于其他研究中单纯手术的结局。
  • 高pCR率和持久缓解可为未来随机试验(包括器官保留策略)提供设计信息。

研究设计与样本

  • 法国多中心单臂2期非随机临床试验,纳入32例cT2-T4NXM0 dMMR/MSI-H胃或GEJ腺癌且适合手术的患者。
  • 干预为纳武利尤单抗240 mg每2周6周期联合伊匹木单抗1 mg/kg每6周2周期新辅助,末次纳武利尤单抗后5周手术,术后纳武利尤单抗480 mg每4周9周期辅助。

主要发现

  • 32例患者中位年龄65岁(范围40-80),女性8例(28%),男性21例(72%),胃癌16例(50%),GEJ癌16例(50%)。
  • 新辅助和辅助治疗相关3/4级不良事件分别发生于6例(19%)和4例(17%)。
  • 中位随访48.3个月(95% CI 44.8-52.0),32例ITT人群4年OS为84.1%(95% CI 65.8%-93.0%),31例可手术者4年EFS为83.5%(95% CI 64.8%-92.8%)。
  • 1例复发脑转移,6例死亡(2例与胃癌或治疗相关:1例术后并发症、1例脑转移;4例无关),29例手术患者中17例(59%)达pCR。

临床怎么用

  • 对于局部dMMR/MSI-H胃或GEJ腺癌,可考虑新辅助纳武利尤单抗联合伊匹木单抗方案,但需注意尚缺乏与单纯手术的随机对照证据。
  • 治疗期间需监测免疫相关不良事件,3/4级不良事件在新辅助和辅助阶段分别约19%和17%。
  • 未手术者均达临床完全缓解,支持未来探索器官保留策略的可行性。

局限性

  • 单臂非随机设计,无同期对照组,无法直接比较单纯手术或其他治疗。
  • 样本量较小(32例),结果需更大规模随机试验验证。
  • 部分患者未完成计划治疗或未手术,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Neoadjuvant nivolumab plus ipilimumab in localized deficient mismatch repair/microsatellite instability-high gastric or gastroesophageal junction (GEJ) adenocarcinoma was evaluated in the NEONIPIGA study. The primary end point of pathological complete response (pCR) was previously reported. OBJECTIVE: To report long-term follow-up results and secondary end points, including event-free survival (EFS) and overall survival (OS), of the NEONIPIGA study. DESIGN, SETTING, AND PARTICIPANTS: The NEONIPIGA study is a French, multicenter, single-arm, phase 2 nonrandomized clinical trial that included patients with histologically proven cT2-T4NXM0 deficient mismatch repair/microsatellite instability-high GEJ adenocarcinoma who were eligible for surgery. Patients were enrolled between October 23, 2019, and June 4, 2021, and the database was locked on November 13, 2025. INTERVENTION: Neoadjuvant nivolumab, 240 mg, every 2 weeks for 6 cycles plus ipilimumab, 1 mg/kg, every 6 weeks for 2 cycles, followed by surgery 5 weeks after the last nivolumab dose, and adjuvant nivolumab, 480 mg, every 4 weeks for 9 cycles. MAIN OUTCOMES AND MEASURES: EFS and OS. RESULTS: A total of 32 patients (median [range] age, 65 [40-80] years; 8 [28%] female and 21 [72%] were male) were included: 16 (50%) with gastric cancer and 16 (50%) with GEJ cancer. Three patients did not undergo surgery (1 with metastatic disease and 2 who refused). Twenty-seven patients (84%) completed neoadjuvant therapy and 14 (44%) received all treatment as planned. Neoadjuvant and adjuvant therapy-related grade 3/4 adverse events occurred in 6 (19%) and 4 patients (17%), respectively. Median follow-up was 48.3 months (95% CI, 44.8-52.0 months). Among the 32 patients in the intention-to-treat population, 4-year OS was 84.1% (95% CI, 65.8%-93.0%). In the 31 patients eligible for surgery, 4-year EFS was 83.5% (95% CI, 64.8%-92.8%). One patient relapsed with cerebral metastases. Six deaths occurred: 2 related to gastric cancer or treatment (1 patient had postoperative complications and 1 cerebral metastases) and 4 unrelated. All patients who did not undergo surgery achieved a clinical complete response after immune checkpoint inhibitor therapy. One patient subsequently died of causes unrelated to their cancer. Overall, 17 of 29 patients (59%) achieved pCR on surgical specimen. Safety was previously reported, and no additional late toxic effects were observed. CONCLUSIONS AND RELEVANCE: In this phase 2 nonrandomized clinical trial, the immunotherapy regimen evaluated was associated with sustained long-term survival, but no clear evidence of improved survival over outcomes reported in other studies evaluating surgery alone in this patient population was observed. The high pCR rates and durable responses observed may provide useful information for designing future clinical studies, including randomized trials investigating organ-preserving strategies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04006262.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Samaille T, Henriques J, Tougeron D, et al. Nivolumab-Ipilimumab for Localized Microsatellite Instability-High Gastric/Gastroesophageal Junction Adenocarcinoma: The Phase 2 NEONIPIGA Nonrandomized Clinical Trial. JAMA Oncol. 2026. PMID: 42879140. doi:10.1001/jamaoncol.2026.4162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。